Female Health FHCO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Female Health FHCO

VERU 2.965

-1.5%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Savant	4/16/2025 11:00:55 AM
	of 211

Veru Inc (NASDAQ: VERU) has announced its participation in the 2nd Annual GLP-1-Based Therapeutics Summit scheduled for April 29 - May 1, 2025, in Boston, Massachusetts. The company will present findings from their Phase 2b QUALITY Clinical Study focusing on how Enobosarm maintained lean mass and physical function in elderly patients using Semaglutide for weight loss. The presentation is scheduled for April 30, 2025, at 12:30 PM EST at the Wyndham Boston Beacon Hill. This appearance aligns with Veru's focus on developing innovative medicines for cardiometabolic and inflammatory diseases. Veru Reveals Phase 2b Data on Enobosarm-Semaglutide Combination Study \| VERU Stock News

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next